Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curasight AS's book value per share for the quarter that ended in Mar. 2026 was kr0.14.
During the past 12 months, Curasight AS's average Book Value Per Share Growth Rate was 78.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -39.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -36.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Curasight AS was 51.60% per year. The lowest was -54.30% per year. And the median was -23.00% per year.
Curasight AS's current price is kr16.75. Its book value per share for the quarter that ended in Mar. 2026 was kr0.14. Hence, today's PB Ratio of Curasight AS is 117.13.
During the past 8 years, the highest P/B Ratio of Curasight AS was 128.67. The lowest was 0.00. And the median was 0.00.
Curasight AS (XSAT:CURAS) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Curasight AS Book Value per Share Related Terms
Curasight AS Book Value per Share Historical Data
* Premium members only.
The historical data trend for Curasight AS's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CURAS vs VRTX, REGN, RVMD: Book Value per Share Comparison
For the Biotechnology subindustry, Curasight AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curasight AS PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Curasight AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where Curasight AS's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curasight AS (XSAT:CURAS) has a Book Value per Share of kr0.14 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Curasight AS and its competitors.
Is Curasight AS's Book Value per Share too high?
Curasight AS's current Book Value per Share is kr0.14. Overall, Curasight AS has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Curasight AS's Book Value per Share compare to VRTX and REGN?
Curasight AS's Book Value per Share of kr0.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Curasight AS and its competitors. Curasight AS's current Book Value per Share is kr0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curasight AS stock overvalued right now?
Curasight AS (XSAT:CURAS) has a current Book Value per Share of kr0.14. The current Book Value per Share is kr0.14. Curasight AS's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Curasight AS (XSAT:CURAS), the current Book Value per Share is kr0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curasight AS is a clinical-stage radiopharmaceutical company based in Copenhagen, Denmark, developing uTREAT, a first-in-class uPAR-targeted radioligand therapy (RLT) platform designed to treat aggressive solid tumors. The Company is focused on advancing its diagnostic and therapeutic platforms through key clinical milestones.
24GF Score
Get the complete analysis for XSAT:CURAS
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CURAS has been successfully added to your 
